Progress in Parkinson’s: from early signs to personalised intervention

Join me for an interview of Prof. Alastair Noyce from the Queen Mary University of London Centre for Preventive Neurology as we explore how the latest data revolution is unlocking personalized medicine and biological sub-types for Parkinson's. We will dive into the shift toward a 'biological staging' model, early detection, discussing how close we are to definitive blood or skin tests and what early biomarkers mean for you. Crucially, the webinar will focus on actionable insights: how you can use targeted lifestyle interventions—like exercise, diet, and gut health management—to build brain resilience and alter disease trajectory.

Alastair Noyce is a Professor in Neurology and Neuroepidemiology at the Wolfson Institute of Population Health, Queen Mary University of London (QMUL), and a Consultant Neurologist at Barts Health NHS Trust where he sees a large number of individuals with movement disorders and other neurological problems.

Alastair graduated from Barts and the London School of Medicine and Dentistry in London in 2007. He pursued integrated training via the Foundation Academic Programme at Barts Health/QMUL and an NIHR Academic Clinical Fellowship at UCL. Between 2012-2016 he undertook a PhD in Neuroscience at UCL. Between 2014-2016 he undertook an MSc in Epidemiology at London School of Hygiene and Tropical Medicine.

In 2017, he rejoined QMUL at the newly created Preventive Neurology Unit (PNU). The PNU grew to become the Centre of Preventive Neurology in September 2023. His research group at the CPN focuses on Parkinson’s disease and other neurodegenerative disorders, particularly early identification and epidemiology, which includes environmental, clinical and genetic determinants.

His group receives funding from Parkinson’s UK, Cure Parkinson’s, Barts Charity, Michael J Fox Foundation, Aligning Science Across Parkinson’s, UKRI and Innovate UK. He has published more than 260 research papers.